YMAB Y-mAbs Therapeutics
- 17.150
- -0.100-0.58%
- 17.150
- 0.0000.00%
Y-mAbs Therapeutics News
Y-mAbs Therapeutics Board Member Dr. Ber Announces Resignation
Y-mAbs to Announce First Quarter 2024 Financial and Operating Results on May 7, 2024
PDF Version The Company will host a conference call and webcast on Wednesday, May 8, 2024 at 8:00 a.m. ETNEW YORK, April 26, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "
Y-mAbs Therapeutics (NASDAQ:YMAB) Rises 9.6% This Week, Taking One-year Gains to 161%
Little Excitement Around Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) Revenues
With a price-to-sales (or "P/S") ratio of 7.8x Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) may be sending bullish signals at the moment, given that almost half of all the Biotechs companies in the United
Y-mAbs Therapeutics Down Nearly 11%, on Pace for Largest Percent Decrease Since November 2022 -- Data Talk
Y-mAbs Therapeutics, Inc. (YMAB) is currently at $14.42, down $1.77 or 10.93% --Would be lowest close since March 18, 2024, when it closed at $13.76 --On pace for largest percent decrease since Nov.
Selling US$1.9m Of Stock Was Lucrative Decision For Y-mAbs Therapeutics Insiders
Y-mAbs Therapeutics, Inc.'s (NASDAQ:YMAB) stock rose 10% last week, but insiders who sold US$1.9m worth of stock over the last year are probably in a more advantageous position. Selling at an average
Y-Mabs Therapeutics CFO Resigns, Ensures Smooth Transition
Y-mAbs Therapeutics Has Commenced a Search Process for a Successor >YMAB
Y-mAbs Therapeutics Has Commenced a Search Process for a Successor >YMAB
Press Release: Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-st
Y-mAbs Therapeutics Chief Fincl Officer Bo Kruse Has Resigned >YMAB
Y-mAbs Therapeutics Chief Fincl Officer Bo Kruse Has Resigned >YMAB
Y-mAbs Therapeutics Announces Resignation of Chief Financial Officer
PDF Version NEW YORK, March 14, 2024 (GLOBE NEWSWIRE) -- Y-mAbs Therapeutics, Inc. (the "Company" or "Y-mAbs") (Nasdaq: YMAB), a commercial-stage biopharmaceutical company focused on the developm
Y-mAbs Therapeutics(YMAB.US) Officer Sells US$64,116 in Common Stocks
$Y-mAbs Therapeutics(YMAB.US)$ Officer Gad Thomas sold 3,900 shares of Common Stocks on Mar 5, 2024 at an average price of $16.44 for a total value of $64,116.Source: Announcement What is statement of
Y-mAbs Therapeutics(YMAB.US) Officer Sells US$28,282.83 in Common Stocks
$Y-mAbs Therapeutics(YMAB.US)$ Officer Rajah Vignesh sold 1,711 shares of Common Stocks on Mar 5, 2024 at an average price of $16.53 for a total value of $28,282.83.Source: Announcement What is statem
Y-mAbs Therapeutics(YMAB.US) Officer Sells US$27,837.1 in Common Stocks
$Y-mAbs Therapeutics(YMAB.US)$ Officer Smith Susan Laura sold 1,682 shares of Common Stocks on Mar 5, 2024 at an average price of $16.55 for a total value of $27,837.1.Source: Announcement What is sta
Cracking The Code: Understanding Analyst Reviews For Y-mAbs Therapeutics
Ratings for Y-mAbs Therapeutics (NASDAQ:YMAB) were provided by 4 analysts in the past three months, showcasing a mix of bullish and bearish perspectives.In the table below, you'll find a summary of th
Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Y-mAbs Therapeutics Is Maintained at Buy by HC Wainwright & Co.
Express News | HC Wainwright & Co. Maintains Buy on Y-mAbs Therapeutics, Raises Price Target to $22
Y-mAbs Therapeutics Price Target Raised to $26.00/Share From $22.00 by Canaccord Genuity
Y-mAbs Therapeutics Price Target Raised to $26.00/Share From $22.00 by Canaccord Genuity
Y-mAbs Therapeutics Is Maintained at Outperform by BMO Capital
Y-mAbs Therapeutics Is Maintained at Outperform by BMO Capital
Express News | BMO Capital Maintains Outperform on Y-mAbs Therapeutics, Raises Price Target to $26
Analysis
Price Target
No Data
